Compliance Rate
Compliance Rate
0.0%
Compliant submissions
0
Incompliant submissions
1
Total trials
1
My Organizations' Clinical Trials
Showing 50 of 1949 entries
View as:
Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/30/05
End: 05/31/08
Due: 05/31/09
Phase: N/A
Priority: Normal
Start: 10/31/09
End: 11/30/13
Due: 11/30/14
Phase: N/A
Priority: Normal
Start: 03/31/16
End: 08/06/18
Due: 08/06/19
Phase: N/A
Priority: Normal
Start: 04/25/23
End: 05/30/24
Due: 05/30/25
Phase: N/A
Priority: Normal
Start: 11/04/19
End: 01/19/22
Due: 01/19/23
Phase: N/A
Priority: Normal
Start: 03/31/13
End: 04/30/16
Due: 04/30/17
Phase: N/A
Priority: Normal
Start: 05/01/17
End: 03/06/20
Due: 03/06/21
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 02/28/14
Due: 02/28/15
Phase: N/A
Priority: Normal
Start: 05/04/17
End: 04/30/37
Due: 04/30/38
Phase: N/A
Priority: Normal
Start: 11/23/16
End: 08/13/21
Due: 08/13/22
Phase: N/A
Priority: Normal
Start: 05/31/04
End: 12/31/06
Due: 12/31/07
Phase: N/A
Priority: Normal
Start: 10/20/21
End: 07/31/22
Due: 07/31/23
Phase: N/A
Priority: Normal
Start: 03/01/23
End: 01/06/26
Due: 01/06/27
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 06/30/14
Due: 06/30/15
Phase: N/A
Priority: Normal
Start: 07/31/13
End: 06/30/15
Due: 06/30/16
Phase: N/A
Priority: Normal
Start: 11/23/20
End: 12/13/21
Due: 12/13/22
Phase: N/A
Priority: Normal
Start: 12/31/21
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 09/03/14
End: 02/14/22
Due: 02/14/23
Phase: N/A
Priority: Normal
Start: 09/07/16
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 05/17/23
End: 01/17/25
Due: 01/17/26
Phase: N/A
Priority: Normal
Start: 08/31/09
End: 09/30/13
Due: 09/30/14
Phase: N/A
Priority: Normal
Start: 07/31/15
End: 10/31/17
Due: 10/31/18
Phase: N/A
Priority: Normal
Start: 01/06/17
End: 06/25/19
Due: 06/25/20
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 01/10/19
Due: 01/10/20